NCT05961111View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 24, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
SarcomaCarcinomaDigestive CancerBreast CancerLung CancerBrain CancerMelanomaGynecologic CancerHead and Neck CancerKidney Cancer
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type 1 (R130)

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

276000

RECRUITING

Linyi Central Hospital, Linyi

All Listed Sponsors
collaborator

Linyi People's Hospital

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY